Palma Jose-Alberto, Norcliffe-Kaufmann Lucy, Kaufmann Horacio
Department of Neurology, Dysautonomia Center, New York University School of Medicine, NY, USA.
Department of Neurology, Dysautonomia Center, New York University School of Medicine, NY, USA.
Auton Neurosci. 2018 May;211:15-25. doi: 10.1016/j.autneu.2017.10.007. Epub 2017 Oct 23.
Multiple system atrophy (MSA) may be difficult to distinguish clinically from other disorders, particularly in the early stages of the disease. An autonomic-only presentation can be indistinguishable from pure autonomic failure. Patients presenting with parkinsonism may be misdiagnosed as having Parkinson disease. Patients presenting with the cerebellar phenotype of MSA can mimic other adult-onset ataxias due to alcohol, chemotherapeutic agents, lead, lithium, and toluene, or vitamin E deficiency, as well as paraneoplastic, autoimmune, or genetic ataxias. A careful medical history and meticulous neurological examination remain the cornerstone for the accurate diagnosis of MSA. Ancillary investigations are helpful to support the diagnosis, rule out potential mimics, and define therapeutic strategies. This review summarizes diagnostic investigations useful in the differential diagnosis of patients with suspected MSA. Currently used techniques include structural and functional brain imaging, cardiac sympathetic imaging, cardiovascular autonomic testing, olfactory testing, sleep study, urological evaluation, and dysphagia and cognitive assessments. Despite advances in the diagnostic tools for MSA in recent years and the availability of consensus criteria for clinical diagnosis, the diagnostic accuracy of MSA remains sub-optimal. As other diagnostic tools emerge, including skin biopsy, retinal biomarkers, blood and cerebrospinal fluid biomarkers, and advanced genetic testing, a more accurate and earlier recognition of MSA should be possible, even in the prodromal stages. This has important implications as misdiagnosis can result in inappropriate treatment, patient and family distress, and erroneous eligibility for clinical trials of disease-modifying drugs.
多系统萎缩(MSA)在临床上可能难以与其他疾病区分开来,尤其是在疾病的早期阶段。仅表现为自主神经症状时,可能无法与纯自主神经功能衰竭相区分。表现为帕金森综合征的患者可能会被误诊为帕金森病。表现出MSA小脑表型的患者可能会模仿其他由酒精、化疗药物、铅、锂和甲苯引起的成人起病性共济失调,或维生素E缺乏,以及副肿瘤性、自身免疫性或遗传性共济失调。仔细的病史采集和细致的神经系统检查仍然是准确诊断MSA的基石。辅助检查有助于支持诊断、排除潜在的模仿疾病并确定治疗策略。本综述总结了对疑似MSA患者进行鉴别诊断有用的诊断性检查。目前使用的技术包括结构和功能脑成像、心脏交感神经成像、心血管自主神经测试、嗅觉测试、睡眠研究、泌尿系统评估以及吞咽困难和认知评估。尽管近年来MSA的诊断工具有所进步,且有临床诊断的共识标准,但MSA的诊断准确性仍不尽人意。随着其他诊断工具的出现,包括皮肤活检、视网膜生物标志物、血液和脑脊液生物标志物以及先进的基因检测,即使在疾病前驱期,也应该能够更准确、更早地识别MSA。这具有重要意义,因为误诊可能导致不适当的治疗、患者和家属的痛苦以及疾病修饰药物临床试验的错误入选资格。